Wockhardt Ltd
NSE: WOCKPHARMA BSE: 532300
₹1347.20
(2.38)%
Tue, 03 Feb 2026, 08:36 am
Market Cap224.18B
PE Ratio-
Dividend0
Health Technology
Pharmaceuticals: Major
24.5Kwockhardt ltd History
2000
- Launched cardiac drug enalapril maleate in US through joint venture with Sidmak Laboratories.
- Set up corporate training centre at Aurangabad.
2001
- Wockhardt Hospitals to set up two cardiac hospitals in Mumbai and Bangalore.
- Terminated marketing alliance with Sidmak Laboratories.
- Entered strategic alliance with Eisai Company Ltd for neurology drug Methycobal.
- Wockhardt Hospitals tied up with four international health insurance companies for NRIs.
- Launched employee stock option scheme ESOP.
2002
- Hari L Mundra joined as vice-chairman.
- Appointed Mr. Lalit Kumar as Executive Director.
2003
- Restructured field organization.
- Launched Asia's first human recombinant insulin.
- Launched four speciality hospitals at Mulund complex in Mumbai.
- Maharashtra Government terminated JV agreement for super speciality hospital.
- Acquired CP Pharmaceuticals (Holdings) Ltd and subsidiaries.
- Received US FDA approval for bethanechol chloride tablets.
- Mr. JS Khorakiwala resigned from directorship.
2004
- Filed IND application for new drug WCK-1152.
- Acquired esparma GmbH for $11 million.
- Received US FDA approval for sterile injectable facility and 6 manufacturing units.
2005
- Launched India's first automatic insulin delivery device.
- Forged alliance with Kamineni Group for two heart hospitals in Hyderabad.
- Unveiled Father's Heart Network.
- Received US FDA approval for cefuroxime axetil.
- Launched new Hepatitis A vaccine.
2006
- Waluj plant approved by US FDA.
2007
- Signed in-licensing pact with Crawford Healthcare of UK.
- Appointed Mr. Rajiv B Gandhi as Director- Finance & Information.
- Received US FDA approval for Ketorolac anti-inflammatory injection.
- Acquired Negma Laboratories for $265 million.
2008
- Launched Cetirizine tablets in US.
- Entered 10-year in-licensing pact with Sinclair Pharma to market dermatology and dental products in India.
2009
- Launched new insulin Glaritus in India.
- Announced succession plan under Chairman Habil Khorakiwala.
- Launched anti-hypertensive drug Nicardipine injections in US.
- Won Government of India Patent Award.
- Appointed BDO Haribhakti as auditor.
- Announced Entacapone patent settlement with Orion Corporation.
2010
- Received US FDA approval for antibacterial Levofloxacin.
- Launched prostate drug Flomax in US on Day-1.
- Received US FDA approval for generic version of Toprol XL cardiac drug.
2011
- Launched generic version of Protonix tablets in US.
- Received US FDA approval for generic version of Effexor XR capsules.
- Launched three new products in three weeks in US.
- Received tentative US FDA approval for generic version of Patanol ophthalmic solution.
2012
- Launched generic version of anti-ulcer drug Prevacid.
- Received US FDA approval for generic version of Parkinsonism drug Requip XL.
- Received tentative US FDA approval for generic version of anti-psychotic drug Geodon.
- Received US FDA approval for generic version of Parkinson’s drug Comtan.
2013
- Received 'Best Enterprise' award from Europe.
- Launched generic version of anti-convulsant drug Lamictal XR.
2014
- Drug discovery received fast track approval by US FDA.
2015
- Received ANDA approval for pain medication Oxycodone liquid.
- Received QIDP designation for new drug WCK 4873 from US FDA.
- MHRA completed plant inspection.
2016
- Acquired 100% stake in Wockhardt France (Holdings) S.A.S.
2017
- Received US FDA approval for eye drop for treating ophthalmic allergies.
- Received US FDA acknowledgement for Breakthrough Superdrug Antibiotic WCK 5222 for Phase III clinical trial.
- Received US FDA approval for ANDA 1gm and 2gm injections of oxacillin.
2018
- Set up first manufacturing facility in Middle East for new chemical entities.
2019
- Received US FDA approval for 100mg and 400mg tablets of Imatinib Mesylate.
- Received US FDA approval for prostate cancer drug.
2020
- Entered agreement with UK Government to fill-finish COVID-19 vaccines.
- Received QIDP designation for combination antibiotic WCK 6777 from US FDA.
- Received DCGI approval for 2 new antibiotics.
2021
- Partnered with RDIF to produce Sputnik V and Sputnik Light vaccines against COVID-19.
- Partnered with Jemincare for novel respiratory antibiotic Nafithromycin.
2022
- Issued rights shares of Rs. 5 in the ratio of 3:10 at a premium of Rs. 220 per share.
- Received affirmation in credit ratings from CARE.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800